Globe Life Inc

GL is in a Stage 4 distribution phase with active Lower Highs & Lower Lows confirming supply dominance and a bearish medium-term bias. Short-term timing is unfavorable as price trades below declining EMAs in an oversold context without any reversal signals. Execution should be deferred, trimming into rallies near the 9/20 EMA resistance zone around 172–174. The long-term uptrend remains intact above the 200-day SMA, providing structural support unless decisively broken.

• ↑Q2 2026 net income rose 20% YoY to $288M, driven by 16% health premium growth ($437M).
• ↑Management forecasts ~7% total premium revenue growth in 2026, underscoring durable momentum.
• ↓Negative growth outlook as admin expenses rise 8% YoY and investment income falls 8% to $31M.